ENSYSCE BIOSCIENCES INC (ENSC) Stock Price, Quote, News and Overview
NASDAQ:ENSC - Nasdaq - US2936024056 - Common Stock - Currency: USD
ENSC Quote, Performance and Key Statistics
5.4
-0.23 (-4.09%)
The current stock price of ENSC is 5.4 USD. In the past month the price decreased by -31.99%. In the past year, price decreased by -59.55%.
ENSC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ENSC
Company Profile
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Company Info
ENSYSCE BIOSCIENCES INC
7946 Ivanhoe Avenue, Suite 201
La Jolla CALIFORNIA US
CEO: Daniel B. Silvers
Employees: 7
Company Website: https://ensysce.com/
Investor Relations: https://ir.ensysce.com/
Phone: 18582634196
ENSYSCE BIOSCIENCES INC / ENSC FAQ
What is the stock price of ENSYSCE BIOSCIENCES INC today?
The current stock price of ENSC is 5.4 USD. The price decreased by -4.09% in the last trading session.
What is the ticker symbol for ENSYSCE BIOSCIENCES INC stock?
The exchange symbol of ENSYSCE BIOSCIENCES INC is ENSC and it is listed on the Nasdaq exchange.
On which exchange is ENSC stock listed?
ENSC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ENSYSCE BIOSCIENCES INC stock?
7 analysts have analysed ENSC and the average price target is 53.3 USD. This implies a price increase of 886.94% is expected in the next year compared to the current price of 5.4. Check the ENSYSCE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ENSYSCE BIOSCIENCES INC worth?
ENSYSCE BIOSCIENCES INC (ENSC) has a market capitalization of 5.35M USD. This makes ENSC a Nano Cap stock.
How many employees does ENSYSCE BIOSCIENCES INC have?
ENSYSCE BIOSCIENCES INC (ENSC) currently has 7 employees.
What are the support and resistance levels for ENSYSCE BIOSCIENCES INC (ENSC) stock?
ENSYSCE BIOSCIENCES INC (ENSC) has a resistance level at 6.08. Check the full technical report for a detailed analysis of ENSC support and resistance levels.
Is ENSYSCE BIOSCIENCES INC (ENSC) expected to grow?
The Revenue of ENSYSCE BIOSCIENCES INC (ENSC) is expected to grow by 107.5% in the next year. Check the estimates tab for more information on the ENSC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ENSYSCE BIOSCIENCES INC (ENSC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENSC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENSC, evaluating the profitability, health, valuation and growth aspects
- ENSYSCE BIOSCIENCES INC (ENSC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENSYSCE BIOSCIENCES INC (ENSC) Sales and EPS estimates to see what analysts future expectations are.
- ENSYSCE BIOSCIENCES INC (ENSC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENSYSCE BIOSCIENCES INC (ENSC) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENSYSCE BIOSCIENCES INC (ENSC) Stock Chart to make your own analysis
- ENSYSCE BIOSCIENCES INC (ENSC) Latest news and press-releases to stay up to date.
Does ENSYSCE BIOSCIENCES INC (ENSC) stock pay dividends?
ENSC does not pay a dividend.
When does ENSYSCE BIOSCIENCES INC (ENSC) report earnings?
ENSYSCE BIOSCIENCES INC (ENSC) will report earnings on 2025-03-19, after the market close.
What is the Price/Earnings (PE) ratio of ENSYSCE BIOSCIENCES INC (ENSC)?
ENSYSCE BIOSCIENCES INC (ENSC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.87).
What is the Short Interest ratio of ENSYSCE BIOSCIENCES INC (ENSC) stock?
The outstanding short interest for ENSYSCE BIOSCIENCES INC (ENSC) is 4.2% of its float. Check the ownership tab for more information on the ENSC short interest.
ENSC Technical Analysis
ENSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENSC. The financial health of ENSC is average, but there are quite some concerns on its profitability.
ENSC Financial Highlights
Over the last trailing twelve months ENSC reported a non-GAAP Earnings per Share(EPS) of -11.87. The EPS increased by 46.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.47% | ||
| ROE | -114.75% | ||
| Debt/Equity | 0 |
ENSC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ENSC. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -60.41% and a revenue growth 107.5% for ENSC